Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
ADP-ribosylation factor-like protein 5C (ARL5C) is a member of the Arf-like subfamily of small GTPases in the Ras superfamily. ARL5C is predicted to have GTP binding and GTPase activity and is implicated in critical cellular processes such as intracellular protein transport, protein localization to the Golgi membrane, and vesicle-mediated trafficking, particularly between endosomes and the Golgi apparatus. It plays a role in recruiting the Golgi-associated retrograde protein (GARP) complex to maintain Golgi structure and function. Although ARL5C is less well characterized than other family members, loss of ARL5C function leads to disruptions in Golgi integrity and endosome function. There is currently no evidence directly supporting a role for ARL5C as a therapeutic target, nor are any drug interactions or roles in specific diseases currently established.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on ADP-ribosylation factor-like protein 5C (ARL5C).